NEW YORK, April 18, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Quintana Energy Services Inc. (NYSE:QES), ProQR Therapeutics N.V. (NASDAQ:PRQR), Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), Biomerica, Inc. (NASDAQ:BMRA), Heat Biologics, Inc. (NASDAQ:HTBX), and Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
QES DOWNLOAD: http://Capital-Review.com/register/?so=QES
PRQR DOWNLOAD: http://Capital-Review.com/register/?so=PRQR
TTPH DOWNLOAD: http://Capital-Review.com/register/?so=TTPH
BMRA DOWNLOAD: http://Capital-Review.com/register/?so=BMRA
HTBX DOWNLOAD: http://Capital-Review.com/register/?so=HTBX
BLPH DOWNLOAD: http://Capital-Review.com/register/?so=BLPH
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Capital Review, available for free download at the links above, examine Quintana Energy Services Inc. (NYSE:QES), ProQR Therapeutics N.V. (NASDAQ:PRQR), Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), Biomerica, Inc. (NASDAQ:BMRA), Heat Biologics, Inc. (NASDAQ:HTBX), and Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
QUINTANA ENERGY SERVICES INC. (QES) REPORT OVERVIEW
Quintana Energy Services' Recent Financial Performance
For the twelve months ended December 31st, 2018 vs December 31st, 2017, Quintana Energy Services reported revenue of $604.35MM vs $438.03MM (up 37.97%) and analysts estimated basic earnings per share -$0.50 vs $0.00. Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.44. The estimated EPS forecast for the next fiscal year is $0.29 and is expected to report on March 4th, 2020.
To read the full Quintana Energy Services Inc. (QES) report, download it here: http://Capital-Review.com/register/?so=QES
-----------------------------------------
PROQR THERAPEUTICS N.V. (PRQR) REPORT OVERVIEW
ProQR Therapeutics N.V's Recent Financial Performance
Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.41. The estimated EPS forecast for the next fiscal year is -$1.73 and is expected to report on February 26th, 2020.
To read the full ProQR Therapeutics N.V. (PRQR) report, download it here: http://Capital-Review.com/register/?so=PRQR
-----------------------------------------
TETRAPHASE PHARMACEUTICALS, INC. (TTPH) REPORT OVERVIEW
Tetraphase Pharmaceuticals' Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Tetraphase Pharmaceuticals reported revenue of $4.28MM vs $2.53MM (up 69.42%) and analysts estimated basic earnings per share -$0.40 vs -$0.38. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Tetraphase Pharmaceuticals reported revenue of $18.90MM vs $9.67MM (up 95.57%) and analysts estimated basic earnings per share -$1.37 vs -$2.63. Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.42. The estimated EPS forecast for the next fiscal year is -$1.08 and is expected to report on March 12th, 2020.
To read the full Tetraphase Pharmaceuticals, Inc. (TTPH) report, download it here: http://Capital-Review.com/register/?so=TTPH
-----------------------------------------
BIOMERICA, INC. (BMRA) REPORT OVERVIEW
Biomerica's Recent Financial Performance
For the three months ended February 28th, 2019 vs February 28th, 2018, Biomerica reported revenue of $1.26MM vs $1.38MM (down 8.32%) and basic earnings per share -$0.07 vs -$0.04. For the twelve months ended May 31st, 2018 vs May 31st, 2017, Biomerica reported revenue of $5.56MM vs $5.79MM (down 3.93%) and analysts estimated basic earnings per share -$0.17 vs -$0.11. Analysts expect earnings to be released on August 29th, 2019. The report will be for the fiscal period ending May 31st, 2019. The reported EPS for the same quarter last year was -$0.08. The estimated EPS forecast for the next fiscal year is -$0.32 and is expected to report on August 29th, 2019.
To read the full Biomerica, Inc. (BMRA) report, download it here: http://Capital-Review.com/register/?so=BMRA
-----------------------------------------
HEAT BIOLOGICS, INC. (HTBX) REPORT OVERVIEW
Heat Biologics' Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Heat Biologics reported revenue of $2.06MM vs $0.61MM (up 235.41%) and analysts estimated basic earnings per share $0.28 vs -$0.35. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Heat Biologics reported revenue of $5.79MM vs $1.52MM (up 281.20%) and analysts estimated basic earnings per share -$0.90 vs -$3.08. Analysts expect earnings to be released on May 21st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.75. The estimated EPS forecast for the next fiscal year is -$0.64 and is expected to report on April 4th, 2019.
To read the full Heat Biologics, Inc. (HTBX) report, download it here: http://Capital-Review.com/register/?so=HTBX
-----------------------------------------
BELLEROPHON THERAPEUTICS, INC. (BLPH) REPORT OVERVIEW
Bellerophon Therapeutics' Recent Financial Performance
Analysts expect earnings to be released on May 9th, 2019. The report will be for the fiscal period ending March 31st, 2019. The estimated EPS forecast for the next fiscal year is -$0.38 and is expected to report on March 12th, 2020.
To read the full Bellerophon Therapeutics, Inc. (BLPH) report, download it here: http://Capital-Review.com/register/?so=BLPH
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Morena Zambada, Media Department
Office: +1 (410) 280-7496
E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.